References

1. Rohatagi S, Barrett J. Pharmacokinetic/pharmacodynamic modeling in drug Development. In: Applications of Pharmacokinetic Principles in Drug Development, Ed. Krishna R. Kluwer Academic/ Plenum Publishers 2003

2. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Application, third ed. Williams and Wilkins, Baltimore. 1995

3. Li AP, Ed. Advances in Pharmacology: Drug-Drug Interactions: Scientific and Regulatory Perspectives. San Diego, CA: Academic Press. 1997, pp. 43, 189-203

4. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43(5):443-469

5. Natarajan C, Rohatagi S. Role of Pharmacokinetics in Preclinical Development. In: Industrial Pharmacokinetics, Eds. Bonate P, Howard D. AAPS Press 2004

6. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and Disease. Clin Pharmacol Ther 2005;78:260-277

7. Defining genetic influences on pharmacologic responses. Drug interactions table. Available at http://medicine.iupui.edu/flockhart/

8. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for inter individual differences in drug response. Ann Rev Genomics Human Genetics 2001;2:9-39

9. Kalow W. Pharmacogenetics, pharmacogenomics, and pharma-cobiology. Clin Pharmacol Ther 2001;70(1):1-4

10. FDA Guidance. Bioanalytical method validation. U.S. FOA

11. Chaikin P, Rhodes GR, Rohatagi S, Natarajan C. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective. J Clin Pharmacol 2000;40:1428-1438

12. Guidance for Industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, July 2005

13. U.S. Food and Drug Administration (CDER). Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies (DRAFT GUIDANCE). April 2005.

14. Shah B, Emmons G, Rohatagi S, Martin NE, Howell S, Jensen BK. Mass balance study of 14C-M100240, a dual ACE/NEP inhibitor in healthy male subjects. Am J Ther 2003;10:356-362

15. Rohatagi S, Wang Y, Argenti D. Mass balance studies. In: Industrial Pharmacokinetics, Eds Bonate P, Howard D. AAPS Press, 2004

16. Rohatagi S, Barrett JS, DeWitt KE, Morales, RJ. Integrated pharmacokinetic/metabolic modeling of selegiline after transdermal administration. Biopharm Drug Disp 1997:18(7): 567-584

17. Shi J, Montay G, Bhargava VO. Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial. Clin Pharmacokinet 2005;44(9):915-934

18. Smith B. Assessment of dose proportionality. In: Industrial Pharmacokinetics, Eds. Bonate P, Howard D. AAPS Press. 2004.

19. Vaccaro SK, Argenti D, Shah BS, Gillen MS, Rohatagi S, Jensen BK. Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor. Int J Clin Pharmacol Ther 2000;38(12):588-594

20. Dumas M, d'Athis P, Besancenot JF, Chadoint-Noudeau V, Chalopin JM, Rifle G, Escousse A. Variations of sotalol kinetics in renal insufficiency. Int J Clin Pharmacol Ther Toxicol 1989;27(10):486-489

21. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005;45(7):802-809

22. Rohatagi S, Zannikos PN, DePhillips SL, Ferris O, Boutouyrie BX, Jensen BK. Effect of age on the pharmacokinetics (PK) and pharmacodynamics (PD) of a platelet GP IIB/IIIA antagonist, RPR 109891 (Klerval). 13th Annual Meeting of the American Association of Pharmaceutical Scientists, San Francisco. November 1998.

23. Shi J, Ludden TM, Melikian AP, Gastonguay MR, Hinderling PH. Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. J Pharmacokinet Pharmacodyn 2001;28(6):555-575

24. AAPS Workshop. Integrated roadmap to biomarkers for drug development method validation and qualification. American Association of Pharmaceutical Scientists, September 8-9, 2005

25. Evens RP, Witcher M. Biotechnology: an introduction to recombinant DNA technology and product availability. Ther Drug Monitoring 1993;15(6):514-520

26. Carson KL. Flexibility—the guiding principle for antibody manufacturing. Nature Biotechnology 2005;23(9):1054-1058

Was this article helpful?

0 0
Outsourcing Survival Kit

Outsourcing Survival Kit

Tired Of Being Tied Down By Time? Wish You Could Achieve More And Earn More Within The Deadlines You Are Given? Want To Branch Out To Other Lucrative Areas Without Sacrificing Your Current Business?

Get My Free Ebook


Post a comment